688580 伟思医疗
已收盘 05-18 15:00:01
资讯
新帖
简况
每周股票复盘:伟思医疗(688580)变更办公及联系地址
证券之星 · 05-17 03:11
每周股票复盘:伟思医疗(688580)变更办公及联系地址
伟思医疗(688580)披露关于变更办公及联系地址的公告,5月15日股价上涨0.5%
证券之星 · 05-15 17:40
伟思医疗(688580)披露关于变更办公及联系地址的公告,5月15日股价上涨0.5%
5月10日伟思医疗发布公告,股东减持78.21万股
中金财经 · 05-10
5月10日伟思医疗发布公告,股东减持78.21万股
伟思医疗最新公告:股东志达创投减持1.4453%股份
证券之星 · 05-10
伟思医疗最新公告:股东志达创投减持1.4453%股份
伟思医疗新注册《生物反馈及超声电疗仪软件V1》项目的软件著作权
证券之星 · 05-07
伟思医疗新注册《生物反馈及超声电疗仪软件V1》项目的软件著作权
每周股票复盘:伟思医疗(688580)一季度净利增85.35%
证券之星 · 05-02
每周股票复盘:伟思医疗(688580)一季度净利增85.35%
伟思医疗(688580)2026年一季报简析:营收净利润同比双双增长
证券之星 · 04-29
伟思医疗(688580)2026年一季报简析:营收净利润同比双双增长
伟思医疗(688580)披露作废部分已授予尚未归属的限制性股票公告,4月28日股价上涨2.17%
证券之星 · 04-28
伟思医疗(688580)披露作废部分已授予尚未归属的限制性股票公告,4月28日股价上涨2.17%
图解伟思医疗年报:第四季度单季净利润同比增长50.92%
证券之星 · 04-28
图解伟思医疗年报:第四季度单季净利润同比增长50.92%
伟思医疗:一季度净利增85%,步入可持续增长新阶段
中国财富通 · 04-27
伟思医疗:一季度净利增85%,步入可持续增长新阶段
伟思医疗新注册《上下肢主被动评估康复训练系统管理软件V1》项目的软件著作权
证券之星 · 04-25
伟思医疗新注册《上下肢主被动评估康复训练系统管理软件V1》项目的软件著作权
4月8日伟思医疗涨5.18%,银河康乐股票A基金重仓该股
证券之星 · 04-08
4月8日伟思医疗涨5.18%,银河康乐股票A基金重仓该股
每周股票复盘:伟思医疗(688580)核心技术人员发生变更
证券之星 · 04-05
每周股票复盘:伟思医疗(688580)核心技术人员发生变更
伟思医疗(688580)披露核心技术人员变更公告,4月3日股价下跌1.7%
证券之星 · 04-03
伟思医疗(688580)披露核心技术人员变更公告,4月3日股价下跌1.7%
3月23日伟思医疗跌6.86%,银河康乐股票A基金重仓该股
证券之星 · 03-23
3月23日伟思医疗跌6.86%,银河康乐股票A基金重仓该股
3月20日伟思医疗跌5.64%,银河康乐股票A基金重仓该股
证券之星 · 03-20
3月20日伟思医疗跌5.64%,银河康乐股票A基金重仓该股
中银国际:全球首款侵入式脑机产品获批 行业迈入商业化验证期
智通财经 · 03-16
中银国际:全球首款侵入式脑机产品获批 行业迈入商业化验证期
每周股票复盘:伟思医疗(688580)现两日大宗交易合计超2100万元
证券之星 · 03-15
每周股票复盘:伟思医疗(688580)现两日大宗交易合计超2100万元
伟思医疗(688580)披露股东权益变动触及1%刻度公告,3月13日股价下跌0.68%
证券之星 · 03-13
伟思医疗(688580)披露股东权益变动触及1%刻度公告,3月13日股价下跌0.68%
3月11日伟思医疗现1253.01万元大宗交易
证券之星 · 03-11
3月11日伟思医疗现1253.01万元大宗交易
加载更多
公司概况
公司名称:
南京伟思医疗科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2020-07-21
主营业务:
南京伟思医疗科技股份有限公司的主营业务是医疗器械的研发、生产和销售。公司的主要产品是经颅磁刺激仪、盆底磁刺激仪、脉冲磁场治疗仪、脉冲磁恢复仪、脉冲磁塑形仪、生物刺激反馈仪、立体动态干扰电治疗仪、多参数生物反馈仪、团体生物反馈仪、新生儿脑电测量仪、高频电灼仪、皮秒激光治疗仪、钬激光治疗仪和强脉冲光治疗仪、康复机器人、阴道电极、直肠电极、盆底训练探头、盆底肌肉康复器、高频电极、治疗激光用石英光纤、一次性医用激光光纤、认知功能障碍治疗软件、伟思云。公司先后承担多项国家、省、市各级科研项目,在研发和科技成果转化方面做出了突出贡献,公司是高新技术企业,也是江苏省的企业技术中心、民营科技企业,与此同时公司于2022年被认定为国家级“第四批专精特新‘小巨人’企业”。
发行价格:
67.58
{"stockData":{"symbol":"688580","market":"SH","secType":"STK","nameCN":"伟思医疗","latestPrice":61.15,"timestamp":1779087601000,"preClose":62.18,"halted":0,"volume":1673234,"delay":0,"changeRate":-0.0166,"floatShares":95771299,"shares":95771299,"eps":1.7378,"marketStatus":"已收盘","change":-1.03,"latestTime":"05-18 15:00:01","open":62,"high":62.21,"low":60.7,"amount":103000000,"amplitude":0.0243,"askPrice":61.17,"askSize":6,"bidPrice":61.15,"bidSize":13,"shortable":0,"etf":0,"ttmEps":1.7378,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"adjPreClose":62.18,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":68.4,"lowLimit":55.96,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":95771288,"isCdr":false,"pbRate":3.34,"roa":"--","peRate":35.188169,"roe":"3.57%","epsLYR":1.44,"committee":-0.7,"marketValue":5856000000,"turnoverRate":0.0175,"status":1,"afterMarket":{"amount":0,"volume":0,"close":61.15,"buyVolume":0,"sellVolume":0,"time":1779089637558,"indexStatus":"已收盘 05-18 15:30:00","preClose":62.18},"floatMarketCap":5856000000},"requestUrl":"/m/hq/s/688580","defaultTab":"news","newsList":[{"id":"2636064547","title":"每周股票复盘:伟思医疗(688580)变更办公及联系地址","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636064547?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:11","pubTimestamp":1778958670,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,伟思医疗报收于62.18元,较上周的65.21元下跌4.65%。本周,伟思医疗5月11日盘中最高价报66.5元。本周关注点公司公告汇总:伟思医疗办公及联系地址变更为南京市雨花台区硕果路1号公司公告汇总南京伟思医疗科技股份有限公司因发展需要,将办公及联系地址由南京市雨花台区宁双路19号9栋变更为南京市雨花台区硕果路1号。董事会秘书及证券事务代表联系地址同步变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000943.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700411","title":"伟思医疗(688580)披露关于变更办公及联系地址的公告,5月15日股价上涨0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635700411?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:40","pubTimestamp":1778838052,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,伟思医疗报收于62.18元,较前一交易日上涨0.5%,最新总市值为59.55亿元。该股当日开盘63.0元,最高63.27元,最低61.42元,成交额达1.16亿元,换手率为1.94%。近日,南京伟思医疗科技股份有限公司发布《关于变更办公及联系地址的公告》。公告显示,因发展需要,公司办公及联系地址由南京市雨花台区宁双路19号9栋变更为南京市雨花台区硕果路1号;董事会秘书及证券事务代表联系地址同步变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634447683","title":"5月10日伟思医疗发布公告,股东减持78.21万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634447683","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634447683?lang=zh_cn&edition=full","pubTime":"2026-05-10 19:58","pubTimestamp":1778414283,"startTime":"0","endTime":"0","summary":"证券之星消息,5月10日伟思医疗发布公告《伟思医疗:南京伟思医疗科技股份有限公司关于股东减持股份计划时间届满暨减持结果公告》,其股东南京志达创业投资中心(有限合伙)于2026年3月12日至2026年5月8日间合计减持78.21万股,占公司目前总股本的0.8166%,变动期间该股股价上涨4.34%,截止5月8日收盘报65.21元。股东增减持详情见下表: 根据伟思医疗2026年一季报公布的十大股东详情如下: 为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/10/20260510297427.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/10/20260510297427.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260510/32213193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634444715","title":"伟思医疗最新公告:股东志达创投减持1.4453%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2634444715","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634444715?lang=zh_cn&edition=full","pubTime":"2026-05-10 17:51","pubTimestamp":1778406667,"startTime":"0","endTime":"0","summary":"伟思医疗(688580.SH)公告称,股东志达创投于2026年2月9日至2026年5月8日期间,通过集中竞价和大宗交易方式合计减持公司股份138.42万股,占公司总股本的1.4453%,减持计划时间区间已届满。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000008448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153485","title":"伟思医疗新注册《生物反馈及超声电疗仪软件V1》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633153485?lang=zh_cn&edition=full","pubTime":"2026-05-07 02:00","pubTimestamp":1778090454,"startTime":"0","endTime":"0","summary":"证券之星消息,近日伟思医疗新注册了《生物反馈及超声电疗仪软件V1》项目的软件著作权。今年以来伟思医疗新注册软件著作权4个,较去年同期减少了20%。结合公司2025年年报财务数据,2025年公司在研发方面投入了4511.61万元,同比减10.86%。通过天眼查大数据分析,南京伟思医疗科技股份有限公司共对外投资了11家企业,参与招投标项目1525次;财产线索方面有商标信息226条,专利信息311条,著作权信息121条;此外企业还拥有行政许可212个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","159180","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632962381","title":"每周股票复盘:伟思医疗(688580)一季度净利增85.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632962381","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632962381?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:53","pubTimestamp":1777672392,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,伟思医疗报收于64.26元,较上周的60.23元上涨6.69%。本周,伟思医疗4月30日盘中最高价报68.0元。公司公告汇总长江证券承销保荐有限公司核查确认,伟思医疗2025年度募集资金余额为49,512,428.47元,均存放于指定专户,使用情况符合规定。因2025年营业收入增长率未达股权激励计划设定目标,且首次授予的2名激励对象离职,伟思医疗于2026年4月27日决定作废首次授予及预留授予部分第一个归属期已授予尚未归属的限制性股票共计450,000股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631558807","title":"伟思医疗(688580)2026年一季报简析:营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631558807","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631558807?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:55","pubTimestamp":1777420530,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期伟思医疗发布2026年一季报。根据财报显示,伟思医疗营收净利润同比双双增长。截至本报告期末,公司营业总收入1.06亿元,同比上升10.56%,归母净利润6157.33万元,同比上升85.35%。本次财报公布的各项数据指标表现尚佳。去年的净利率为29.84%,算上全部成本后,公司产品或服务的附加值高。持有伟思医疗最多的基金为创金合信大健康混合A,目前规模为0.33亿元,最新净值0.6647,较上一交易日下跌1.31%,近一年上涨2.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900024356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630775573","title":"伟思医疗(688580)披露作废部分已授予尚未归属的限制性股票公告,4月28日股价上涨2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630775573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630775573?lang=zh_cn&edition=full","pubTime":"2026-04-28 18:07","pubTimestamp":1777370838,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘,伟思医疗报收于63.02元,较前一交易日上涨2.17%,最新总市值为60.36亿元。南京伟思医疗科技股份有限公司于2026年4月28日披露《关于作废部分已授予尚未归属的限制性股票的公告》。公告显示,公司于2026年4月27日召开第四届董事会第九次会议,审议通过《关于作废部分已授予尚未归属的限制性股票的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800054016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630319053","title":"图解伟思医疗年报:第四季度单季净利润同比增长50.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630319053","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630319053?lang=zh_cn&edition=full","pubTime":"2026-04-28 01:45","pubTimestamp":1777311947,"startTime":"0","endTime":"0","summary":"证券之星消息,伟思医疗2025年年报显示,当年度公司主营收入4.63亿元,同比上升15.66%;归母净利润1.38亿元,同比上升35.41%;扣非净利润1.21亿元,同比上升46.04%;其中2025年第四季度,公司单季度主营收入1.37亿元,同比上升26.68%;单季度归母净利润3592.44万元,同比上升50.92%;单季度扣非净利润2778.41万元,同比上升85.59%;负债率11.31%,投资收益1253.33万元,财务费用-285.29万元,毛利率66.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800004849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630994233","title":"伟思医疗:一季度净利增85%,步入可持续增长新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2630994233","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630994233?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:27","pubTimestamp":1777292836,"startTime":"0","endTime":"0","summary":"4月27日晚间,南京伟思医疗科技股份有限公司同步披露了2025年年度报告与2026年第一季度报告,以连贯的高增长业绩彰显发展韧性。年报显示,2025年伟思医疗实现营业收入4.63亿元,同比增长16%;归母净利润1.38亿元,同比大增35%;经营性现金流1.77亿元,同比增长49%,以亮眼成绩强势收官。步入2026年,伟思医疗增长动能进一步释放。研发创新深耕技术护城河,驱动产品多元裂变2025年,伟思医疗研发投入占营收比例达13%,研发人员占比22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=nN8GhrtHfl8%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630782294","title":"伟思医疗新注册《上下肢主被动评估康复训练系统管理软件V1》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2630782294","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630782294?lang=zh_cn&edition=full","pubTime":"2026-04-25 03:52","pubTimestamp":1777060368,"startTime":"0","endTime":"0","summary":"证券之星消息,近日伟思医疗新注册了《上下肢主被动评估康复训练系统管理软件V1》项目的软件著作权。今年以来伟思医疗新注册软件著作权3个,较去年同期减少了40%。通过天眼查大数据分析,南京伟思医疗科技股份有限公司共对外投资了11家企业,参与招投标项目1524次;财产线索方面有商标信息226条,专利信息311条,著作权信息120条;此外企业还拥有行政许可211个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500012150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159180","688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625115389","title":"4月8日伟思医疗涨5.18%,银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625115389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625115389?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:45","pubTimestamp":1775637945,"startTime":"0","endTime":"0","summary":"证券之星消息,4月8日伟思医疗涨5.18%,收盘报54.85元,换手率1.42%,成交量1.36万手,成交额7373.73万元。重仓伟思医疗的公募基金请见下表:该股最近90天内共有3家机构给出评级,买入评级3家;过去90天内机构目标均价为60.0。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为银河基金的银河康乐股票A。银河康乐股票A目前规模为1.41亿元,最新净值2.673,较上一交易日上涨0.38%,近一年上涨32.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800025524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625619043","title":"每周股票复盘:伟思医疗(688580)核心技术人员发生变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2625619043","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625619043?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:40","pubTimestamp":1775331621,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,伟思医疗报收于52.09元,较上周的52.32元下跌0.44%。本周,伟思医疗4月2日盘中最高价报54.36元。本周关注点公司公告汇总:刘文龙不再被认定为核心技术人员,曲振林新任核心技术人员。公司公告汇总南京伟思医疗科技股份有限公司对核心技术人员进行调整,不再认定刘文龙为核心技术人员,其仍留在公司负责市场营销工作。刘文龙在职期间参与研发的知识产权归属公司所有,无知识产权纠纷。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500001082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624545366","title":"伟思医疗(688580)披露核心技术人员变更公告,4月3日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624545366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624545366?lang=zh_cn&edition=full","pubTime":"2026-04-03 18:40","pubTimestamp":1775212827,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,伟思医疗报收于52.09元,较前一交易日下跌1.7%,最新总市值为49.89亿元。该股当日开盘52.82元,最高53.49元,最低52.01元,成交额达4657.55万元,换手率为0.92%。公告显示,刘文龙不再被认定为核心技术人员,其仍留在公司负责市场营销工作;在职期间参与研发的知识产权归属公司所有,无知识产权纠纷。本次调整后,公司核心技术人员由王志愚、仇凯、高飞、刘文龙变更为王志愚、仇凯、高飞、曲振林。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300035874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621776697","title":"3月23日伟思医疗跌6.86%,银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621776697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621776697?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:41","pubTimestamp":1774255316,"startTime":"0","endTime":"0","summary":"证券之星消息,3月23日伟思医疗跌6.86%,收盘报49.68元,换手率2.19%,成交量2.1万手,成交额1.08亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为银河基金的银河康乐股票A。银河康乐股票A目前规模为1.41亿元,最新净值2.628,较上一交易日下跌2.27%,近一年上涨16.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300025436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620866357","title":"3月20日伟思医疗跌5.64%,银河康乐股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620866357","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620866357?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:19","pubTimestamp":1773994741,"startTime":"0","endTime":"0","summary":"证券之星消息,3月20日伟思医疗跌5.64%,收盘报53.34元,换手率2.26%,成交量2.17万手,成交额1.19亿元。重仓伟思医疗的公募基金请见下表:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家;过去90天内机构目标均价为60.0。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为银河基金的银河康乐股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000027602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688580"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619458178","title":"中银国际:全球首款侵入式脑机产品获批 行业迈入商业化验证期","url":"https://stock-news.laohu8.com/highlight/detail?id=2619458178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619458178?lang=zh_cn&edition=full","pubTime":"2026-03-16 16:05","pubTimestamp":1773648327,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中银国际发布研报称,近日,国家药监局批准博睿康植入式脑机接口手部运动功能代偿系统创新产品注册申请,实现脑机接口全球首发上市,标志中国脑机接口产业从“技术验证”迈向“商业化落地”。投资建议随着全球首款侵入式产品获批上市,国内脑机接口产业已进入商业化验证期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中银国际:全球首款侵入式脑机产品获批 行业迈入商业化验证期","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301293","002173","688273","688626","BK0077","688580","BK0114","BK0096","301363","BK0236","BK0251","300753","301087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619178382","title":"每周股票复盘:伟思医疗(688580)现两日大宗交易合计超2100万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619178382","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619178382?lang=zh_cn&edition=full","pubTime":"2026-03-15 02:45","pubTimestamp":1773513912,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,伟思医疗报收于62.41元,较上周的56.71元上涨10.05%。本周关注点来自交易信息汇总:3月10日至11日伟思医疗连续两日发生大宗交易,合计金额超2100万元。公司公告汇总南京伟思医疗科技股份有限公司控股股东王志愚及其一致行动人南京志达创业投资中心于2026年2月9日至3月11日期间,通过集中竞价和大宗交易方式合计减持公司股份602,143股,占总股本的0.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619198824","title":"伟思医疗(688580)披露股东权益变动触及1%刻度公告,3月13日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198824","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619198824?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:23","pubTimestamp":1773393798,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,伟思医疗报收于62.41元,较前一交易日下跌0.68%,最新总市值为59.77亿元。公司于2026年3月13日发布《关于股东权益变动触及1%刻度的提示性公告》。公告显示,控股股东王志愚及其一致行动人南京志达创业投资中心于2026年2月9日至3月11日期间,通过集中竞价和大宗交易方式合计减持公司股份602,143股,占总股本的0.63%。本次权益变动后,王志愚及其一致行动人合计持股比例由46.51%减少至45.88%,触及1%比例变动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618948546","title":"3月11日伟思医疗现1253.01万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2618948546","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618948546?lang=zh_cn&edition=full","pubTime":"2026-03-11 17:21","pubTimestamp":1773220894,"startTime":"0","endTime":"0","summary":"证券之星消息,3月11日伟思医疗发生大宗交易,交易数据如下:近三个月该股共发生9笔大宗交易,合计成交4307.0手,折价成交9笔。该股近期无解禁股上市。截至2026年3月11日收盘,伟思医疗(688580)报收于62.5元,上涨3.25%,换手率4.49%,成交量4.3万手,成交额2.67亿元。该股近半年内有股东持股变动,合计净减持117.68万股,股东增减持明细如下表:该股最近90天内共有6家机构给出评级,买入评级3家,增持评级3家;过去90天内机构目标均价为60.0。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100028825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688580","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779090194790,"stockEarnings":[{"period":"1week","weight":-0.0465},{"period":"1month","weight":0.0715},{"period":"3month","weight":0.085},{"period":"6month","weight":0.2981},{"period":"1year","weight":0.3702},{"period":"ytd","weight":0.2847}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京伟思医疗科技股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"10297人(较上一季度增加24.00%)","perCapita":"9300股","listingDate":"2020-07-21","address":"江苏省南京市雨花台区宁双路19号9栋","registeredCapital":"9577万元","survey":" 南京伟思医疗科技股份有限公司的主营业务是医疗器械的研发、生产和销售。公司的主要产品是经颅磁刺激仪、盆底磁刺激仪、脉冲磁场治疗仪、脉冲磁恢复仪、脉冲磁塑形仪、生物刺激反馈仪、立体动态干扰电治疗仪、多参数生物反馈仪、团体生物反馈仪、新生儿脑电测量仪、高频电灼仪、皮秒激光治疗仪、钬激光治疗仪和强脉冲光治疗仪、康复机器人、阴道电极、直肠电极、盆底训练探头、盆底肌肉康复器、高频电极、治疗激光用石英光纤、一次性医用激光光纤、认知功能障碍治疗软件、伟思云。公司先后承担多项国家、省、市各级科研项目,在研发和科技成果转化方面做出了突出贡献,公司是高新技术企业,也是江苏省的企业技术中心、民营科技企业,与此同时公司于2022年被认定为国家级“第四批专精特新‘小巨人’企业”。","listedPrice":67.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伟思医疗(688580)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伟思医疗(688580)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伟思医疗,688580,伟思医疗股票,伟思医疗股票老虎,伟思医疗股票老虎国际,伟思医疗行情,伟思医疗股票行情,伟思医疗股价,伟思医疗股市,伟思医疗股票价格,伟思医疗股票交易,伟思医疗股票购买,伟思医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伟思医疗(688580)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伟思医疗(688580)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}